Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

FDA Approves Triple Therapy Polypill for High Blood Pressure

News Daily News

FDA Approves Triple Therapy Polypill for High Blood Pressure

Michael O'Riordan

June 10, 2025

FDA Approves Aprocitentan for Inadequately Controlled Hypertension

News Daily News

FDA Approves Aprocitentan for Inadequately Controlled Hypertension

Michael O'Riordan

March 20, 2024

FDA Grants MACE Reduction Indication for Semaglutide

News Daily News

FDA Grants MACE Reduction Indication for Semaglutide

March 08, 2024

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

News Daily News

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Michael O'Riordan

April 29, 2022

FDA Approves Rilonacept to Treat Recurrent Pericarditis and to Curb Recurrences

News Daily News

FDA Approves Rilonacept to Treat Recurrent Pericarditis and to Curb Recurrences

March 25, 2021

FDA Approves Dalteparin Sodium as First Anticoagulant For Use in Pediatric VTE Patients

News Daily News

FDA Approves Dalteparin Sodium as First Anticoagulant For Use in Pediatric VTE Patients

Yael L. Maxwell

May 16, 2019

Diabetes Drug Canagliflozin Gets MACE Reduction Indication

News Daily News

Diabetes Drug Canagliflozin Gets MACE Reduction Indication

November 01, 2018

Implantable Cardiac Monitor for High-Risk ACS Patients Wins FDA Approval

News Daily News

Implantable Cardiac Monitor for High-Risk ACS Patients Wins FDA Approval

Michael O'Riordan

May 08, 2018

Andexanet Alfa, First Reversal Agent for Factor Xa Inhibitors, Finally Gains FDA Approval

News Daily News

Andexanet Alfa, First Reversal Agent for Factor Xa Inhibitors, Finally Gains FDA Approval

May 04, 2018

Bad BVS News: Analysis Points to Fast Reaction by Interventionalists to Absorb Safety Issues

News Conference News ACC 2018

Bad BVS News: Analysis Points to Fast Reaction by Interventionalists to Absorb Safety Issues

Michael O'Riordan

March 11, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.